抗精神病薬の市場規模、シェア、成長分析：治療クラス別、疾患別、薬剤別、流通チャネル別、地域別 - 産業予測 2025～2032年

抗精神病薬市場規模は2023年に172億7,000万米ドルと評価され、2024年の182億7,000万米ドルから2032年には286億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.8％で成長する見通しです。

世界の抗精神病薬市場は、メンタルヘルス問題に対する意識の高まりや、早期診断・治療を促進するための政府や医療機関の協調的な取り組みに後押しされ、力強い成長を遂げています。統合失調症や双極性障害などの精神疾患の増加が、第一世代と第二世代の抗精神病薬の需要を牽引しています。長時間作用型注射剤（LAI）や薬理ゲノミクスによるオーダーメイド治療の革新は、患者のアドヒアランスと治療成績を向上させています。市場はまた、リアルタイムの洞察を提供するデジタル治療薬の台頭と相まって、非定型抗精神病薬へのシフトを経験しています。ジョンソン・エンド・ジョンソンによるIntra-Cellular Therapiesの150億米ドル買収など、最近の買収やFDA承認は、精神科医療の進展と、より安全で効果的な治療に対する需要の高まりに対応することを目的とした戦略的投資のハイライトとなっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

抗精神病薬市場規模：治療クラス別& CAGR（2025-2032）

• 市場概要
• 第一世代
• 第二世代
• 第三世代

抗精神病薬市場規模：疾患別& CAGR（2025-2032）

• 市場概要
• 統合失調症
• 双極性障害
• 単極性うつ病
• 痴呆
• その他の疾患

抗精神病薬市場規模：薬剤別& CAGR（2025-2032）

• 市場概要
• リスペリドン
• クエチアピン
• オランザピン
• アリピプラゾール
• ブレクスピプラゾール
• パリペリドンパルミテート
• その他

抗精神病薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局

抗精神病薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（USA）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK）
• GlaxoSmithKline plc（UK）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb（USA）
• H. Lundbeck A/S（Denmark）
• Sumitomo Pharma Co., Ltd.（Japan）
• Alkermes plc（Ireland）
• Dr. Reddy's Laboratories（India）
• Amgen Inc.（USA）
• Sanofi S.A.（France）
• Merck & Co., Inc.（USA）
• Novartis International AG（Switzerland）
• Roche Holding AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）

結論と提言

Antipsychotic Drugs Market size was valued at USD 17.27 billion in 2023 and is poised to grow from USD 18.27 billion in 2024 to USD 28.69 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The global antipsychotic drugs market is witnessing robust growth, fueled by increased awareness of mental health issues and concerted efforts from governments and health organizations to promote early diagnosis and treatment. The rise in mental health disorders, such as schizophrenia and bipolar disorder, is driving demand for both first- and second-generation antipsychotic medications. Innovations in long-acting injectables (LAIs) and tailored therapies through pharmacogenomics are enhancing patient adherence and treatment outcomes. The market is also experiencing a shift towards atypical antipsychotics, coupled with the rise of digital therapeutics that provide real-time insights. Recent acquisitions and FDA approvals, such as Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies, highlight strategic investments aimed at advancing psychiatric care and accommodating the growing demand for safer, effective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antipsychotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antipsychotic Drugs Market Segments Analysis

Global Antipsychotic Drugs Market is segmented by Therapeutic Class, Disease, Drug, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Drug, the market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antipsychotic Drugs Market

A significant factor fueling the growth of the global antipsychotic drugs market is the escalating incidence of mental health disorders, such as schizophrenia and bipolar disorder. As awareness of these conditions rises, there is a growing demand for innovative treatment options as well as improved access to psychiatric care across the globe. This heightened understanding of mental health issues not only drives the development of new therapies but also emphasizes the necessity for comprehensive support systems for individuals affected by these disorders. Consequently, this trend is propelling the expansion of the antipsychotic drug market worldwide.

Restraints in the Antipsychotic Drugs Market

The global antipsychotic drugs market faces notable restraints, primarily due to regulatory challenges and protracted approval processes. These stringent regulations and extended clinical trial requirements hinder the timely introduction of new therapies, thereby impeding the speed at which groundbreaking medications can become available to patients. Such obstacles particularly affect market expansion in regions with rigid regulatory environments, further constraining the overall growth potential of the antipsychotic drug sector. Consequently, manufacturers and stakeholders must navigate these regulatory complexities, which can significantly delay the development and commercialization of innovative treatment options for mental health disorders.

Market Trends of the Antipsychotic Drugs Market

The antipsychotic drugs market is experiencing a notable trend towards the increasing demand for long-acting injectable antipsychotics, driven by the need for improved management of chronic psychiatric disorders such as schizophrenia. These innovative formulations allow for reduced dosing frequency, enhancing patient adherence and overall treatment effectiveness. Notably, pharmaceutical companies are investing in the development of new long-acting injectables that not only ensure sustained therapeutic efficacy but also prioritize patient convenience. This shift reflects a broader understanding of the complexities of mental health treatment, emphasizing the need for solutions that are both effective and user-friendly, positioning long-acting injectables as key players in the market's growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Antipsychotic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Antipsychotic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Antipsychotic Drugs Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

Global Antipsychotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Antipsychotic Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Disease, Drug, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Disease, Drug, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations